KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 33.1%.

  • Emergent BioSolutions' EBITDA Margin rose 111500.0% to 33.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.02%, marking a year-over-year increase of 305500.0%. This contributed to the annual value of 10.42% for FY2024, which is 588100.0% up from last year.
  • As of Q3 2025, Emergent BioSolutions' EBITDA Margin stood at 33.1%, which was up 111500.0% from 1.14% recorded in Q2 2025.
  • Emergent BioSolutions' 5-year EBITDA Margin high stood at 39.13% for Q4 2021, and its period low was 407.0% during Q2 2024.
  • For the 5-year period, Emergent BioSolutions' EBITDA Margin averaged around 32.46%, with its median value being 4.88% (2024).
  • As far as peak fluctuations go, Emergent BioSolutions' EBITDA Margin crashed by -3203200bps in 2024, and later surged by 4081400bps in 2025.
  • Over the past 5 years, Emergent BioSolutions' EBITDA Margin (Quarter) stood at 39.13% in 2021, then plummeted by -143bps to 16.75% in 2022, then rose by 5bps to 15.84% in 2023, then skyrocketed by 69bps to 4.88% in 2024, then skyrocketed by 778bps to 33.1% in 2025.
  • Its EBITDA Margin was 33.1% in Q3 2025, compared to 1.14% in Q2 2025 and 22.46% in Q1 2025.